Questran second advisory committee divided on OTC switch recommendation.
This article was originally published in The Tan Sheet
Executive Summary
QUESTRAN ADVISORY COMMITTEE EVENLY SPLIT ON OTC SUITABILITY after a reconsideration of Bristol-Myers Squibb's application to switch its Questran (cholestyramine) and Questran Light from prescription to OTC status for the treatment of hypercholesterolemia. At a May 13 meeting in Bethesda, Md., members of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committee voted five to five with one abstention on the suitability of the switch.